Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2019; 14(03): 878-882
DOI: 10.4103/ajns.AJNS_246_17
Case Report

A rare case of drug-induced liver injury caused by levetiracetam

Tomohiro Kawaguchi
1   Department of Neurosurgery, Shirakawa Kosei General Hospital, Shirakawa, Fukushima
Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi
,
Teiji Tominaga
1   Department of Neurosurgery, Shirakawa Kosei General Hospital, Shirakawa, Fukushima
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Levetiracetam (LEV) is one of the newest antiepileptic drugs available on the market and is frequently used in neurosurgical patients requiring antiepileptic assistance. LEV is mainly excreted by the kidney with minimal hepatic metabolism, so it is considered to have a low liver toxicity. Drug-induced liver injury (DILI) associated with LEV administration is extremely rare, with only eight reported cases. In this report, we describe the case of a 44-year-old man who was admitted because of generalized convulsion, and LEV administration at a dose of 3000 mg/day was started following a diagnosis of status epilepticus. Laboratory values before LEV administration were as follows: alanine aminotransferase (ALT), 17 IU/L; aspartate transaminase (AST), 41 IU/L; and total bilirubin, 0.59 mg/dL. Viral serology tests for hepatitis B and hepatitis C yielded negative results. Several hours after LEV administration, the patient developed high-grade fever and his liver enzyme levels were found to be elevated. LEV administration was stopped immediately; the peak laboratory values were as follows: ALT, 1,192 IU/L; AST, 3,150 IU/L; and total bilirubin, 2.02 mg/dL. After conservative treatment, the patient's laboratory values were normalized. A drug-induced lymphocyte stimulation test (DLST) was performed and showed a positive response, indicating that the administration of LEV was responsible for DILI in this patient. Clearly, LEV can provoke DILI despite its low liver metabolism profile. Therefore, readministration of the drug should be avoided in such cases. An in vitro examination, such as a DLST, can be useful for ensuring a definitive diagnosis of DILI.

Key-words:

Drug metabolism - drug-induced liver injury - drug-induced stimulation test - levetiracetam

Financial support and sponsorship

Nil.




Publication History

Article published online:
09 September 2022

© 2019. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Logroscino G, Hesdorffer DC, Cascino G, Hauser WA, Coeytaux A, Galobardes B, et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia 2005;46 Suppl 11:46-8.
  • 2 Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB, et al. Status Epilepticus Severity Score (STESS): A tool to orient early treatment strategy. J Neurol 2008;255:1561-6.
  • 3 Crepeau AZ, Treiman DM. Levetiracetam: A comprehensive review. Expert Rev Neurother 2010;10:159-71.
  • 4 Selvaraj V, Madabushi JS, Gunasekar P, Singh SP. Levetiracetam associated acute hepatic failure requiring liver transplantation: Case report. J Neurol 2016;263:814-5.
  • 5 Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013;369:2525-34.
  • 6 Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-26.
  • 7 Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54.
  • 8 Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010;51:615-20.
  • 9 Corsini A, Bortolini M. Drug-induced liver injury: The role of drug metabolism and transport. J Clin Pharmacol 2013;53:463-74.
  • 10 Lewis JH, Kleiner DE. Hepatic injury due to drugs chemicals and toxin in MacSween's Pathology of the Liver. In: Burt AD, Portmann BC, Feffel LD, Eds., Churchill Livingstone, Elsevier, 2006. p. 649-759.
  • 11 Hanatani T, Sai K, Tohkin M, Segawa K, Kimura M, Hori K, et al. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale. Pharmacoepidemiol Drug Saf 2014;23:984-8.
  • 12 Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008;14:6774-85.
  • 13 Azar NJ, Aune P. Acute pancreatitis and elevated liver transaminases after rapid titration of oral levetiracetam. J Clin Neurosci 2014;21:1053-4.
  • 14 Broli M, Provini F, Naldi I, Bisulli F, Sama C, Baruzzi A, et al. Unexpected gamma glutamyltransferase rise increase during levetiracetam monotherapy. Epileptic Disord 2010;12:81-2.
  • 15 Gutiérrez-Grobe Y, Bahena-Gonzalez JA, Herrera-Gomar M, Mendoza-Diaz P, García-López S, González-Chon O, et al. Acute liver failure associated with levetiracetam and lacosamide combination treatment for unspecified epileptic disorder. Case Rep Emerg Med 2013;2013:634174.
  • 16 Khoury T, Chen S, Abu Rmeileh A, Daher S, Yaari S, Benson AA, et al. Acute liver injury induced by levetiracetam and temozolomide co-treatment. Dig Liver Dis 2017;49:297-300.
  • 17 Sethi NK, Sethi PK, Torgovnick J, Arsura E, Cukierwar F. Asymptomatic elevation of liver enzymes due to levetiracetam: A case report. Drug Metabol Drug Interact 2013;28:123-4.
  • 18 Tan TC, de Boer BW, Mitchell A, Delriviere L, Adams LA, Jeffrey GP, et al. Levetiracetam as a possible cause of fulminant liver failure. Neurology 2008;71:685-6.
  • 19 Xiong N, Hou L, Lu N, Mohamed AA, Wang T, Huang Y, et al. Probable levetiracetam-related serum alkaline phosphatase elevation. BMC Neurol 2012;12:97.
  • 20 Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond) 2016;16:s104-9.
  • 21 Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59:809-20.
  • 22 Beers MH, Berkow R. Hypersensiticity to drugs. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station: Merck & Ci., Inc.; 1999. p. 1064-7.
  • 23 Mantani N, Kogure T, Tamura J, Shimada Y, Terasawa K. Lymphocyte transformation test for medicinal herbs yields false-positive results for first-visit patients. Clin Diagn Lab Immunol 2003;10:479-80.